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Pharmacology of cyclooxygenase-2 inhibition in the kidney. to support physiologic functions, including gastric muco-
Cyclooxygenase (COX) exists as two unique isoforms (that is, sal defense and platelet aggregation. The COX-2 isoform
COX-1 and COX-2) which are poorly understood with regard also is constitutive in some tissues, but unlike COX-1,to their roles in renal function. The renal effects of conventional
this isozyme is markedly induced by bacterial endotox-non-steroidal anti-inflammatory drugs (NSAIDs) are believed to
ins, cytokines and growth factors, and catalyzes the syn-result from the inhibition of one or both isoforms. Drugs that
selectively inhibit COX-2 provide useful pharmacological tools thesis of pro-inflammatory PGs.
for discerning the effects associated with the inhibition of the The antagonism of inflammation and pain by NSAIDs
individual isoforms, and may help clarify the renal roles of COX-1 is believed to result from the inhibition of COX-2, whileand COX-2. This review summarizes the current data on the
the antagonism of gastric mucosal defense and platelet ag-renal expression of COX isoforms and their potential roles in
gregation are the results of COX-1 inhibition [5–7]. Clini-renal function, and reviews the studies that have attempted
to correlate renal functional changes with selective isoform cal doses of NSAIDs non-selectively inhibit COX-1 and
inhibition. Since there are significant differences in the expres- COX-2 [8–13]. Thus, therapeutic use of these rather use-
sion of COX isoforms in the kidneys of laboratory animals and ful drugs is limited by significant clinical toxicity, includ-humans, this review also examines the correlation of the results
ing gastrointestinal (GI) ulceration, perforation, obstruc-of COX inhibition in experimental studies in laboratory ani-
tion, and bleeding. Drugs that selectively inhibit COX-2mals with clinical data. Because of potential interspecies differ-
ences in the roles of COX isoforms in renal function, animal now are available, including celecoxib (Celebrex), val-
models may have limited predictive value for patients, particu- decoxib (Bextra), and rofecoxib (Vioxx). These possess
larly those with renal risk factors. Accordingly, any uncertainty anti-inflammatory properties similar to naproxen, ibupro-concerning the safety or therapeutic benefit of COX-2-specific
fen, and diclofenac; but unlike conventional non-selectivedrugs in these patient populations will need to be resolved with
NSAIDs, they spare COX-1 at clinical doses. This greatlyclinical investigations.
mitigates the adverse effects in the GI tract as well as
bleeding secondary to diminished platelet function.
In the early 1970s, Vane hypothesized that the thera- Now it is known that the biological role of COX-2
peutic action and toxicity of non-steroidal anti-inflamma- extends beyond inflammation and pain (Fig. 1). Early fe-
tory drugs (NSAIDs) were based on the inhibition of the male reproductive function (for example, ovulation, im-
enzyme cyclooxygenase (COX) that catalyzes the com- plantation and decidualization) is dependent on COX-2.
mitted step in the synthesis of prostaglandins (PGs) [1]. Numerous reports suggest that certain forms of pre-
Almost two decades later, an accumulation of in vitro cancerous lesions and cancer, including renal and blad-
and in vivo evidence supported a new hypothesis: that two der cancer, over-express COX-2 [14–20]. Therefore, it
distinct isoforms of COX exist, including one that is in- is likely that research will continue to identify potential
duced selectively by pro-inflammatory stimuli [2]. Several roles for COX-2 in disease and normal physiology, as
laboratories confirmed the existence of two genes that well as discover new therapeutic applications of COX-2-
encode distinct isoforms of COX (COX-1 and COX-2) specific drugs.
in 1991 [3, 4]. The COX-1 isoform is constitutive in many Renal physiology is partially COX-dependent, and PGs
organs and cells and catalyzes the PG synthesis believed are active in regulating vascular tone and salt and water
homeostasis by modulating glomerular hemodynamics
and regulating distal nephron function [21, 22]. There-Key words: kidney, renal failure, hypertension, congestive heart failure,
macula densa, COX-1, COX-2. fore, some consequence of the inhibition of COX activity
in the kidney is not unexpected. In fact, COX inhibitionReceived for publication May 15, 2001
is believed to be the basis of some adverse renal effectsand in revised form August 28, 2001
Accepted for publication November 12, 2001 of NSAIDs, including acute ischemic renal failure, fluid
and electrolyte disturbances, and, possibly, renal papil- 2002 by the International Society of Nephrology
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function across species; (2) basal COX-1 and COX-2
activities may be redundant in kidneys of higher species,
including humans; and, (3) COX-1 and COX-2 may sup-
port different aspects of renal function in lower species.
Based on immunoreactivity data, the renal consequence
of COX-1 inhibition might be expected to be similar
across species, while COX-2 inhibition may have differ-
ent consequences in the kidneys of lower animals com-
pared with humans. In any case, the significant differ-
ences in COX expression between laboratory animals
and humans suggest that extrapolation of findings with
Fig. 1. Differential roles of cyclooxygenase-1 (COX-1) and COX-2 in COX inhibitors in animals to humans may not be simple.physiological and pathological processes.
CONSEQUENCES OF COX INHIBITION IN
THE KIDNEYlary necrosis (RPN) [23–25]. Given the propensity of
The kidney is a target of NSAIDs and the renal activityNSAIDs to cause renal side effects, there is keen interest
observed with these drugs reflects multiple points of drugin the renal safety of COX-2-specific drugs. Recently,
action along the nephron. Local PG synthesis in the kid-a large body of data has been published on the renal
ney supports important roles in the regulation of renalexpression of COX-1 and COX-2 and the renal effects
function and homeostasis (Table 1). Therefore, these ef-of non-selective NSAIDs versus COX-2 selective agents.
fects likely reflect pharmacological inhibition of renalThis review provides a perspective on the current data
COX-1 and/or COX-2. Currently, the relationship of spe-relating to cyclooxygenase inhibition in the kidney, par-
cific COX isoforms to renal function is not well under-ticularly with anti-inflammatory therapeutic agents that
stood [34]; however, the available immunoreactivity dataare based on COX inhibition.
does suggest that simple relationships are not likely, and
that COX isoforms may support a region-specific, and
CYCLOOXYGENASE EXPRESSION IN KIDNEYS even redundant, function in the kidney (abstract; Stan-
OF HUMANS AND LABORATORY ANIMALS field et al, Vet Pathol 37:558, 2000) [31, 35–37]. Studies
Unlike the GI tract and platelet, in which physiological that have attempted to characterize the functional conse-
function is dependent on COX-1, the kidneys of both quences of inhibition of specific COX isoforms are sum-
laboratory species (rat and dog) and primates (cynomol- marized in this review.
gus monkeys and humans) constitutively express both
COX-1 and COX-2 [16, 26–31]. COX-1 immunoreactiv-
SODIUM EXCRETIONity is abundant and appears uniformly across species in
the collecting ducts, renal vasculature, glomeruli, and Natriuresis, or sodium excretion, is stimulated by in-
creases in renal interstitial volume and is PG-dependentpapillary interstitial cells (Fig. 2).
In contrast, basal COX-2 immunoreactivity in kidney [38]. Sodium retention (antinatriuresis) is a consequence
of NSAID use in some patients [24]. COX-1 is highlyis less intense and exhibits some interspecies differences
in localization. The intrarenal distribution of COX-2 in expressed in the collecting ducts of both laboratory ani-
mals and humans, an area of the nephron that is activerats and dogs includes the macula densa (Fig. 2), thick
ascending limbs of loop of Henle (TAL), and papillary in the regulation of sodium excretion [21]. In addition,
COX-2 is co-localized with Na,K-ATPase in the thickinterstitial cells. COX-2 immunoreactivity also has been
reported in the intercalated cells of the cortical collecting ascending limb of the rat nephron, further suggesting a
role in sodium regulation in that species [36]. Studiesduct in the mouse [32]. In normal humans and non-
human primates, COX-2 is co-localized with COX-1 in included in the preclinical safety database for celecoxib
reported transient antinatriuresis in rats up through sixglomeruli and small blood vessels of the kidney but is
not detectable in the macula densa [29–31]. Recently, it weeks of treatment at systemic exposures that were
within the index of COX-2 selectivity. Prostaglandin E2was shown that COX-2 is detectable in the macula densa
in elderly humans (60 years of age) [33]. These authors (PGE2) concentrations in renal tissue, but not urine, con-
comitantly were decreased at these exposures suggestingsuggested that this COX-2 expression in elderly subjects
may be secondary to decreased basal renin production that the antinatriuretic effect might partly be related to
inhibition of COX-2-dependent PGs. The lack of effectassociated with aging.
In summary, it may be inferred from these observa- of celecoxib on basal urine PGE2 concentrations may rep-
resent sparing of a COX-1-dependent PG pool. Gross,tions that: (1) COX-1 may fulfill similar roles in renal
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Fig. 2. Immunohistochemical localization of COX-1 in the collecting ducts and papillary interstitial cells (arrows) (A) and COX-2 in the macula
densa (B) of canine kidney. Note the lack of COX-2 in the macula densa (arrow) of non-human primate kidney (C). (Reproduction of this figure
in color was made possible by Pharmacia.)
Table 1. Constitutive expression of cyclooxygenase inhibition in the kidney
Location COX-1 COX-2 Prostaglandins Possible functions
Glomerulus   PGE2, PGI2 Podocyte contractility and maintenance of GFR
Thick ascending limb of
loop of Henle  a PGE2 Enhance excretion of sodium and chloride
Macula densa  a PGE2 Regulation of renin release; mediates
tubuloglomerular feedback
Collecting ducts  b PGE2 Enhance excretion of sodium, chloride, and water
Papillary interstitial cells   PGE2, TXA2 Enhance vasodilatation and natriuresis
Renal vasculature   PGE2, PGI2, TXA2 Regulation of regional blood flow, antagonism of
angiotensin II-induced vasoconstriction
Sources: [16, 26, 28, 30–33, 35, 55, 56, 58].
a Not seen in normal human and non-human primates, but seen in elderly humans
b Observed in mouse only
Dwyer and Knox have shown a sparing of sodium excre- The up-regulation of COX-2 expression observed in
the cortex under conditions of low salt intake was notedtion with COX-2-selective inhibitors during forced diu-
resis [39]. by Yang and his co-workers [40] to be consistent with a
role for COX-2 in the preservation of cortical circulationOther studies suggest that COX-2 is up-regulated in
response to increased salt load and volume overload. in the volume-contracted state. This role of COX-2 in
Yang and co-workers characterized the COX-2 expres- volume contraction is discussed in greater detail else-
sion in the kidneys of rats subjected to either high or low where in this review. Clearly, their study’s results illus-
salt dietary intake for seven days [40]. COX-2 mRNA trate the potential for multiplicity of PG function and
was increased up to 4.5-fold in the inner medulla by high regulation in various regions of the kidney. The recipro-
salt diet whereas no change in COX-2 mRNA was ob- cal decrease in COX-2 expression in the cortex provides
served with the low salt diet. In contrast, cortical COX-2 evidence that COX-2 is regulated differentially in specific
mRNA was altered by both high and low salt dietary regions of the kidney in response to changes in functional
regimens: a 2.9-fold decrease was observed with the high demands on the kidney.
salt diet, whereas a 3.3-fold increase was observed with
the low salt diet. COX-1 mRNA was not affected in any
BASAL RENAL BLOOD FLOWregion of the kidney with either diet. The expression of
A few studies tried to elucidate the roles of COXCOX-2 was localized primarily in the macula densa and
isoforms in renal blood flow in normal animals. For ex-cortical TAL, and medullary interstitial cells. The authors
ample, Brooks and co-workers studied the effects ofsuggest that the increased expression of COX-2 in the
indomethacin, a potent non-selective NSAID, 6-MNAmedullary interstitium may promote excretion of excess
(the active metabolite of nabumetone), and celecoxibsodium in response to increased pressure (that is, stretch)
and volume overload in the medullary interstitium. on renal blood flow in normal conscious dogs following
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Fig. 3. Potential interactions between the re-
nin-angiotensin-aldosterone (RAA) axis and
COX-2 in the macula densa. Angiotensin and
aldosterone directly or indirectly regulate re-
nin production and release and maintain intra-
vascular volume homeostasis. Under basal
conditions, constitutive COX-2 in the macula
densa of rats and dogs may modulate renin
release. In humans, conditions that result in
perturbation of volume homeostasis or hyper-
reninemia (such as congestive heart failure)
lead to induction of COX-2 in the macula
densa and increased prostaglandin synthesis.
Local prostaglandins are responsible for auto-
regulating against vasoconstriction of the re-
nal afferent arteriole produced by angiotensin,
thus maintaining renal hemodynamics. Ab-
breviations are: JG cells, juxtaglomerular cells;
MD, macula densa; Ang II, angiotensin II;
PGs, prostaglandins; EA, efferent arteriole;
AA, afferent arteriole.
intravenous administration [41]. Only celecoxib was re- vasoconstriction effect of angiotensin II to maintain renal
ported to decrease renal blood flow, which was attributed perfusion in the hyper-renin state. The consequences of
to its COX-2-selective action. The data for this study, how- selective inhibition of COX isoform(s) in the volume-
ever, raise some questions. Failure to control for vehicle contracted state have been investigated in several labora-
effect of the organic solvent used for intravascular deliv- tory studies.
ery of celecoxib, and the unexplained lack of effect with Regulation of renin secretion. There is some evidence
the positive control, indomethacin, limit the conclusions that COX-2-mediated PG synthesis supports volume ho-
regarding pharmacological inhibition of COX. meostasis in lower animal species. For example, stimuli
In contrast, SC-046, a COX-2–selective inhibitor closely for RAA activation increase renal COX-2 expression in
related to celecoxib, given orally to normal conscious rats and dogs as evidenced by increased COX-2 immuno-
dogs produced no diminution of renal blood flow at doses
reactivity and mRNA in a hyper-renin state induced withthat produced plasma concentrations adequate for maxi-
salt restriction [26, 31]. The induction of COX-2 is seenmal and selective inhibition of COX-2 (abstract; Free-
in those regions where this isoform occurs constitutively,man et al, FASEB J, 13:A722, 1999). These results were
that is, the macula densa and TAL [26, 31]. Other studiescorroborated by a study using another COX-2-selective
have shown that the induction of COX-2 in the maculaagent, nimesulide [42]. COX-2 selective doses of this
densa is coordinated functionally with increased reninagent, confirmed by the absence of an effect on platelet
secretion [40, 43–45]. In response, the RAA exerts nega-aggregation, were found to produce no effect on mean ar-
tive feedback on cortical macula densa COX-2 expres-terial blood pressure, glomerular filtration, or renal blood
sion and thus, renin secretion [46, 47]. When angio-flow in normal dogs. Decreases in sodium excretion,
urine volume, and lithium excretion were observed with tensin-II production is blocked by administration of an
nimesulide, which were considered as tubular effects. angiotensin-converting enzyme (ACE) inhibitor to vol-
Collectively, these two studies suggest that COX-2 does ume-contracted rats, the feedback inhibition of COX-2
not govern basal renal blood flow in laboratory animals. expression is lost, leading to increased renin secretion
[46–48]. Further molecular evidence on the significance
of macula densa COX-2 as an important mediator ofVOLUME-CONTRACTED STATES
RAA was shown in COX-2 knockout mice that failedProstaglandins appear to be active in volume homeo-
to exhibit increases in renin production in response tostasis through two mechanisms. First, as part of the renin-
ACE inhibition [49].angiotensin-aldosterone (RAA) axis, PGs promote the
These mechanisms, however, may not apply univer-release of renin from the kidney in response to loss of
intravascular volume (Fig. 3). Second, PGs counter the sally to other species. It has been reported that volume
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contraction induced by salt restriction in non-human pri- sulide decreased renal blood flow and urinary PGE2 lev-
els in dogs rendered volume-contracted with low sodiummates does not increase renal COX-2 expression, al-
though plasma renin levels were elevated [31]. The rela- and diuretic treatment, along with increases in mean ar-
terial blood pressure and, at higher doses, decreases intionship between COX-2 expression and renin secretion
for the human kidney remains unknown; but the observa- glomerular filtration [42]. Interestingly, nimesulide did
not affect plasma renin activity as might be expectedtions in the volume-contracted rats do form a basis for the
well-recognized ability of NSAIDs to antagonize the blood based on the role of COX-2 in renin release.
Clinical studies with rofecoxib and indomethacin inpressure-lowering effect of ACE inhibitors in patients.
salt-depleted subjects show that both drugs produce some
Renal perfusion in the hyper-renin state decrease in renal blood flow evident as a decrease in
glomerular filtration [53]. However, the salt depletionLocal autoregulation by PGs maintains kidney perfu-
sion by countering vasoconstriction of the afferent renal model in humans reflects a relatively mild volume distur-
bance that may not reflect the more severe volume dis-arteriole that occurs with activation of the RAA axis
[21, 22]. Ichihara, Imig and Navar employed a cannulated turbance that is critical in the progression and manage-
ment of hepatic disease seen in cirrhotic patients [54].juxtaglomerular nephron preparation to study the affer-
ent arteriolar response to increased perfusion pressure Hepatic cirrhosis can be produced in rats by treatment
with carbon tetrachloride, and the resulting morphologi-with a COX-2-selctive inhibitor, NS-398 [50]. The affer-
ent arteriolar diameter decreased in control preparations cal and hemodynamic changes are remarkably similar to
the human disease. Using this model, Bosch-Marce et alwhen perfusion pressure was increased; the addition of
10 mol/L NS-398 to the perfusate did not affect the ba- demonstrated that renal plasma flow was diminished by
approximately the same extent after administration of asal diameter, although afferent arteriolar constriction
was enhanced with increasing perfusion pressure. These COX-2-selective inhibitor, SC-236 (33%), or ketorolac
(34%) [54]. The nadir for the decreased renal plasma flowresults indicate that PG synthesis by COX-2 may be
important in autoregulation of the renal afferent arteri- was more prolonged and lasted more than one hour with
ole diameter in the face of vasoconstrictive influences. ketorolac, whereas the effect with SC-236 was relatively
When the nephron was transected at the loop of Henle transient and lasted about 20 minutes. The more pro-
(that is, papillectomy), the effect of NS-398 on arteriolar nounced effect with ketorolac possibly reflects a greater
diameter was lost, presumably due to the loss of tubulo- decrease in renal PGs as a result of its non-selective in-
glomerular feedback by COX-2 in the macula densa, an hibition of both COX isoforms. A very interesting finding
anatomical site where COX-2 expression is increased in the Bosch-Marce study [54] was that the relative ex-
with activation of the RAA. pression of COX-1 and COX-2 isoforms was nearly iden-
Studies with COX-2-selective and non-selective inhib- tical in the kidney in both control and cirrhotic rats.
itors have been conducted to evaluate the COX gover- The finding that COX-2 expression was not increased in
nance of renal blood flow in volume-contracted animals. cirrhotic rats suggests that renal plasma flow may not be
Black and colleagues found that renal blood flow is sig- governed by a single COX isoform in this model, unlike
nificantly reduced in volume-contracted dogs by indometh- the salt-depletion model of volume contraction.
acin at plasma concentrations that produce maximal In summary, different patterns of COX-dependency
inhibition of both COX isoforms, whereas MF-Tricyclic, of renal blood flow are predicted in various models of
a COX-2-selective inhibitor, produced no effect on renal volume contraction in animals and humans. Clearly, salt-
blood flow [51]. The plasma concentrations of MF-Tri- depletion in the dog and human predicts for different
cyclic were sufficient to produce only half-maximal inhi- outcomes with renal COX-2 inhibition than the cirrhotic
bition of COX-2, thus leaving open the possibility that rat, making it difficult to draw conclusions on the conse-
the full pharmacological effect of the compound was quence of COX-2-selective inhibition for the severely
not achieved. volume-contracted, hyper-renin, patients.
Other investigations used a different approach in which
anesthetized dogs rendered volume-contracted by salt
RENAL PAPILLARY NECROSISdepletion and treatment with furosemide were given ei-
Renal papillary necrosis caused by NSAID use in hu-ther SC-560, an experimental COX-1-selective inhibitor,
mans is rare, and usually is associated with the simultane-or ketorolac, a non-selective inhibitor [52]. SC-560 pro-
ous presence of other risk factors, such as, age, atheroscle-duced selective and maximal COX-1 inhibition but did
rotic heart disease, congestive heart failure, concomitantnot affect renal blood flow, whereas ketorolac produced
use of diuretics, dehydration and analgesic (acetamino-maximal inhibition of both isoforms and diminished re-
phen and phenacetin) abuse [55–59]. In contrast, NSAIDsnal blood flow. From these results, it was inferred that the
readily produce renal papillary necrosis in dogs and ratseffect of ketorolac is attributed to inhibition of COX-2.
Rodriguez and co-workers also demonstrated that nime- that appears sensitive to renal papillary injury for a vari-
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ety of reasons related to papillary structure and tortuos- tion rate and urinary PGs without remarkable changes
ity of renal blood flow [60]. This form of nephrotoxicity in serum creatinine, and are consistent with a mild, pro-
can be seen in these species even after acute exposures gressive ischemic etiology. The restriction of these changes
with sub-therapeutic doses of NSAIDs, including indo- to the outer cortex differentiates them from both acute
methacin, nabumetone, and meloxicam (abstract; Khan ischemic insult characterized by acute tubular necrosis
et al, Vet Pathol 34:509, 1997) [37, 61]. throughout the cortex, and wedge-shaped focal ischemic
The mechanism(s) of renal papillary necrosis are poorly cortical necrosis resulting from obstruction of the arcuate
understood despite the appearance of this toxicity across artery. Outer cortical lesions resembling those observed
a broad range of chemicals [61]. It is speculated that the in dogs have not been observed in adult humans follow-
papillae of rats and dogs are susceptible to chemical in- ing treatment with NSAIDs. This may reflect interspecies
sult due to sluggish regional blood flow that predisposes differences in renal anatomy and/or the expression and
to ischemia and accumulation of toxic substances. Thus, distribution of COX isoforms, especially COX-2 [31].
local inhibition of papillary PG synthesis and disruption
of regional blood flow may play a role in NSAID-induced
RENAL DEVELOPMENT AND FUNCTION INrenal papillary necrosis. NSAID-induced renal papillary
THE FETUSnecrosis is initially manifested as morphological changes
of loss of extracellular matrix and degeneration of the A potential role of COX-2 in fetal renal development
interstitial cells of the papilla; thus, these cells are likely is suggested by the available data. Recently, it was shown
the early targets of NSAIDs [62]. Since interstitial cells that neither COX-2 mRNA or protein are detectable in
of the renal papilla in rats and dogs show approximately rat fetal tissues during embryonic days 7 to 13, which co-
equal expression of both COX-1 and COX-2, it might incide with the critical periods of organogenesis. How-
be difficult to correlate the papillary injury seen with ever, COX-2 expression was observed consistently in
non-selective NSAIDs with inhibition of a specific COX several fetal tissues including kidneys in mid to late preg-
isoform. However, renal papillary necrosis was not ob- nancy and up to two weeks after birth (abstract; Stanfield
served in preclinical toxicology studies with celecoxib et al, Vet Pathol 37:558, 2000). These observations sug-
(abstract; Khan et al, Vet Pathol 34:509, 1997) while it was gest that COX-2 may not be critical in the earlier periods
readily produced by non-selective NSAIDs (meloxicam of organogenesis, but possibly has a role in organ growth
and nabumetone). After 52 weeks of dosing, total cele- and differentiation thereafter. Similarly, we have demon-
coxib concentrations measured in the papilla of rats were strated a prominent age-related change in the distribu-
approximately 1000-fold the IC50 for COX-2 (40 nmol/L) tion and intensity of COX-2 expression in fetal and neo-
and threefold the IC50 for COX-1 (15 mol/L). Estimates natal dogs (abstract; Khan et al, Vet Pathol 35:486, 1999).
of free concentrations of this highly bound drug would COX-2 expression was absent in the metanephric struc-
support the conclusion that papillary COX-2 was maxi- tures, but intense COX-2 immunoreactivity appeared in
mally inhibited while any inhibition of COX-1 was sub- the macula densa and TAL associated with the immature
maximal. Therefore, it may be inferred that COX-2 inhi- nephrons adjacent to the metanephric regions, and di-
bition alone is not a primary target in NSAID-induced minished in the well-developed nephrons of the inner
interstitial cell death. cortex. After one day postpartum, COX-2 immunoreac-
While renal papillary necrosis is a rare clinical event tivity declined progressively and appeared in fewer neph-
seen with NSAIDs, the failure to produce this toxicity
rons and cells, until gradually reaching the localization
with a COX-2–selective inhibitor in sentinel species sug-
and intensity previously described for adult dogs within
gests that these drugs may offer some increment in renal
two to four weeks [31]. This two to four week period co-safety over non-selective NSAIDs. Assuming that com-
incides with postnatal renal development in rats and dogs.plete ablation of papillary COX activity is required for
In contrast to the normal adult kidney, the human fe-renal papillary necrosis, there may be little risk for renal
tal kidney at four to six months of gestation exhibits dif-papillary necrosis with COX-2-selective drugs since COX-1
fuse moderate to marked COX-2 immunoreactivity in theis the principal isoform in the human papilla [30, 31].
macula densa and the TAL [64]. As with the rat and dog
kidneys, a gradient in COX-2 immunoreactivity exists from
ATROPHY OF SUBCAPSULAR CORTEX immature nephrons adjacent to metanephric regions to
the well-developed inner cortical nephrons. This high ex-Dogs given NSAIDs, like naproxen, at doses that are
pression of COX-2 in the immature nephrons in rats, dogs,tolerated over long periods develop a progressive tubular
and humans may signify some role in fetal renal develop-atrophy and interstitial fibrosis that primarily is limited
ment and function. It is noted that in conjunction withto the outer renal cortex [63]. These typically mild lesions
COX-2, fetal kidneys exhibit high renin mRNA and pro-are associated with modest elevations in blood urea nitro-
gen and decreases in renal blood flow, glomerular filtra- tein levels that shift with maturation from a widespread
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Table 2. Conditions associated with increased renal COX-2 expression
Condition Observed in species Location Reference
Congestive heart failure Human Macula densa [28, 71]
Hypertension Human Macula densa [71]
Diabetic nephropathy Human Macula densa [71]
Bartter’s syndrome Human Macula densa [28]
Volume contraction Rat, dog Macula densa, TAL [26, 31, 75]
NSAID therapy Rat Macula densa, TAL, papillary interstitial cells [37]
Nephritides Human Glomerulus (macrophages) [29]
Renal development Rat, dog, human Macula densa, TAL [64, 76] (abstract; Khan et al,
Vet Pathol 35:486, 1999)
Renal cell carcinoma Dog Neoplastic cells [77]
distribution along the intrarenal vasculature to a narrow presence of risk factors such as age, atherosclerotic heart
locus in the wall of the afferent arteriole [65]. disease, congestive heart failure, hypertension, diabetes,
The functional significance of COX-2 in renal develop- concomitant use of diuretics or analgesic abuse. In the
ment in rodents is evident from studies in COX-2 knock- presence of one or more of these risk factors, there is a
out mice in which the gene for COX-2 has been deleted predisposition for NSAID-induced diminution of renal
[66, 67]. These animals are born with apparently normal blood flow, electrolyte disturbances, and histopathologi-
kidneys expected for the neonatal mice but during early cal changes in the kidney that may reflect the loss of
postnatal periods develop marked morphologic alter- compensatory action by PGs [31, 37, 51].
ations characterized by immature glomeruli, tubular at- Cyclooxygenase-2 immunoreactivity has been observed
rophy, basophilic tubular epithelium, proteinuria, and in the renal parenchyma of human subjects with various
interstitial fibrosis. Eventually, most of these mice die renal diseases as well as from animal models (Table 2).
of renal failure. Recently, Komhoff and colleagues also However, it cannot be discerned with immunoreactivity
have demonstrated that inhibition of COX-2 in the neo- alone that this isoform is supporting renal compensatory
natal rat can impair glomerulonephrogenesis and pro- mechanisms active in these diseases.
duce renal cortical damage [68]. However, it should be As an example, COX-2 protein or mRNA is not found
noted that in contrast with humans where the kidney is in the macula densa of normal human kidneys. In con-
fully developed at birth, renal maturation in rats and trast, the kidneys of elderly subjects [33] and patients
dogs continues for another two to four weeks after birth; with a clinical history of diabetic nephropathy, conges-
therefore, extrapolation of the rodent data to human tive heart failure, or hypertension exhibit mild to moder-
neonates is questionable. ate COX-2 immunoreactivity in some macula densa and
Renal data with human fetuses exposed to non-selec- the TAL [71]. Nevertheless, the presence of COX-2 in
tive NSAIDs during the third trimester, however, do sug- these specimens may have little if anything to do with
gest an adverse effect of in utero COX inhibition on the the underlying disease and may be explained by other
human kidney based on morphologic changes similar to factors. NSAIDs, for example, are reported to increase
those seen in the COX-2 knockout mouse or to those re- COX-2 expression in the macula densa [37], making it
ported in the neonatal rat kidneys following administra- possible that the immunoreactivity observed in these
tion of selective COX-2 inhibitors [69, 70]. The potential specimens simply may reflect patient use of these rather
role of the COX-2 isoform in prenatal nephron develop- common drugs.
ment therefore poses an uncertainty for obstetrical-gyne- The significance of COX-2 expression in renal disease
cological applications of any COX-2 inhibitor (non-selec- becomes clear in cases where these data are corroborated
tive or selective) that might result in fetal exposure. by functional assessments. This is illustrated by the role
Collectively, the renal pathology in the COX-2 knock- for COX-2 in hyper-filtration suggested by Sanchez and
out mouse, the expression of COX-2 in fetal kidneys, co-workers [72] based on studies with remnant kidneys.
and the appearance of renal pathology in the kidneys in Renal ablation was modeled in rats with unilateral ne-
human fetuses exposed to NSAIDs suggest that COX-2
phrectomy and partial occlusion of the afferent arteriolemay be involved in fetal renal development and renal
in the contralateral kidney. This procedure producedfunction.
several changes over the course of seven days, including:
increased mean arterial pressure, approximately three-
IDENTIFICATION OF POTENTIAL RENAL RISK fold increases in urine volume, threefold decreases in
FACTORS FOR COX INHIBITORS urine osmolality, and twofold increases in urine protein
concentrations. Increases were seen in COX-2 proteinThe occurrence of adverse renal effects with conven-
tional NSAIDs often is exacerbated by the underlying and mRNA along with concomitant increases in urinary
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Table 3. Concordance for results from animal models and clinical outcomes
Renal effect Agent Animal models Clinical results
Na excretion Celecoxib Decrease (normal rat) Decrease
Rofecoxib a Decrease
Basal RBF Celecoxib No effect (normal rat) No effect
Rofecoxib a No effect
RBF in compromised kidney MF-Tricyclic No effect (salt-depleted dog) a
Nimesulide Decrease (salt-depleted dog) a
SC-236 No effect (cirrhotic rat) a
Rofecoxib a Decrease (salt-depleted subjects)
GFR NS-398 Decrease (renal ablation-rat) a
a Data not available
PGE2 concentrations. Treatment with NS-398 decreased design included 4000 patients receiving celecoxib at a
dose of 400 mg BID (twofold the maximum arthritisurine volume, urinary protein concentration, and urinary
PGE2 concentrations; thus, inhibition of COX-2 abated dose), and 2000 patients who received standard thera-
peutic doses of either diclofenac (75 mg BID) or ibupro-the decline in renal function produced by this model.
While these results suggest that COX-2–selective drugs fen (800 mg TID). Although the primary purpose was
to collect data on endpoints related to gastrointestinalmay have clinical benefit in patients with reduced func-
tional renal mass, they also underscore the necessity of safety, the study broadly included evaluations of cardio-
vascular, hemostasis, hepatic and renal function.functional assessments in understanding the functional
significance of COX expression in the kidney. The incidence of any renal adverse event in celecoxib-
treated patients was similar to patients receiving diclo-
fenac, and less than the incidence in patients receivingCLINICAL STUDIES WITH
ibuprofen. The incidence of withdrawals due to adverseCOX-2–SELECTIVE INHIBITORS
renal events was small and similar across all treatment
Because both COX-1 and COX-2 likely play some role groups. Similar, but low, incidences of emergent hyper-
in renal function, clinical differentiation of COX-2–spe- tension, aggravated hypertension, and edema (general-
cific inhibitors from conventional non-selective NSAIDs ized and peripheral) were seen with celecoxib and di-
may not be as clear in the kidney. This possibility is under- clofenac; whereas patients receiving ibuprofen exhibited
scored by recent studies with celecoxib and rofecoxib significantly higher incidences of emergent hypertension,
in healthy elderly subjects [35, 73]. Mild and transient generalized edema, and peripheral edema compared with
sodium retention that reiterated the effect seen with the celecoxib group. A higher percentage of patients in
naproxen and indomethacin (the comparator drugs in both of the non-selective NSAID groups exhibited labo-
these studies) was observed with both COX-2–specific ratory values that were suggestive of diminished renal
drugs. Both studies suggest that sodium excretion in hu- blood flow (that is, BUN 40 mg/dL and/or creatinine
mans can be regulated by COX-2. On the other hand, 2 mg/dL) compared with the celecoxib group. Collec-
neither COX-2–specific drug affected glomerular filtra- tively, these results show that celecoxib possesses some
tion, in contrast with the decreases seen with both non- advantage in renal safety over non-selective NSAIDs
selective NSAIDs. Thus, it can be inferred that COX-1 based on its COX-1-sparing action.
governs basal glomerular filtration in healthy individuals
(that is, those without the risk factors previously dis-
CONCLUSIONScussed). Thus, COX-2–specific inhibitors produce some
mild disturbance of sodium excretion that is characteris- The availability of COX-2-specific drugs has contrib-
uted to progress in understanding the renal consequencestic of conventional NSAIDs, but unlike NSAIDs, these
drugs spare glomerular filtration. The latter represents of COX inhibition in the kidney, particularly in normal
patients with reasonably intact renal function. Undera clinical advantage for COX-2–specific agents in the
treatment of elderly patients in which glomerular filtra- basal conditions, the results of COX inhibition predicted
from animal models (that is, sodium retention and spar-tion already is deteriorating.
Recently, these conclusions were confirmed for cele- ing of glomerular filtration) are in agreement with clinical
outcomes seen with drugs like celecoxib and rofecoxibcoxib by the results of a six-month safety study in arthritis
patients [74]. This study, termed the Celecoxib Long- within their windows of COX-2-selectivity (Table 3).
Uncertainty still remains concerning clinical outcomesterm Arthritis Safety Study (CLASS), was conducted to
compare the incidence of ulcer complications in patients with COX-2-specific drugs in patients with renal risk fac-
tors. As discussed in this review, results with animal modelsreceiving celecoxib or conventional NSAIDs. The study
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